Skip to main content

Apheresis Unit (Hematology)

Apherisis is a procedure that makes it possible to separate the various elements of the blood, in particular: 

  • the plasma (therapeutic plasmapherisis),
  • the red corpuscles (therapeutic erythropheresis),
  • the white corpuscles (therapeutic leucapheresis),
  • the hematopoietic stem cells (cytapheresis), essential for both analogous transplants (using cells taken from the patient) and allogenic transplants (using the cells of another donor). 

Apheresis is a technique of extraction by centrifugation in an extracorporeal blood circuit (CEC). The components not collected are reinjected into the donor. 

The Apheresis Unit at the Jules Bordet Institute receives, for the ULB-IRIS network as a whole, patients likely to benefit from the collection of stem cells. The Unit works in close cooperation with the various autotransplant centres for adults and with the Children's Hospital (HUDERF). 

We have been practicing apheresis in our service since 1970, with a nursing and technical staff trained especially for the purpose. Two doctors and four nurses are available and ensure the continuity of the medical care, in cooperation with the hematology service as a whole. The Unit has an emergency service that operates 24 hours a day. 

The harvest, handling and conservation of the hematopoietic stem cells is in accordance with good practices. Since 2009 we have been accredited under the inspection programme (JACIE, the "Joint Accreditation Committee of the ISCT and EBMT" ) which makes it possible to improve quality within the various teams involved in carrying out the hematopoietic transplants.  

The Apheresis Unit at the Jules Bordet Institute also gives our patients access to treatment using photopheresis. This treatment is indicated for Graft Versus Host Disease that does not respond to the standard treatment and in certain cases of skin lymphomas. 

 

Research projects


 

Project 1

A Phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECP™ for patients with refractory chronic GVHD
  • Project Initiator : Philippe Lewalle
  • Collaboration(s) : Protocole de la société belge d’hématologie
  • Financing (or) support: Amis de l’Institut Bordet

Our team

Responsible Physician
Prof Philippe Lewalle - Hematologist

Doctor
Dr Adriano Salaroli

Head Nurse
Patrick Crombez

Nurse(s)
Corine Mal
Walter Bellemans
Denise Duthoit
Nicoletta Munteanu
Olivier Mugema

Qualitician
Aurélie Timmermans
Olivier Carabin

Secretariat
Vanessa Vanpevenage

13/01/2020

 Scientific publications

Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study.

Authors : Thibaud V, Denève L, Dubruille S, Kenis C, Delforge M, Cattenoz C, Somme D, Wildiers H, Pepersack T, Lamy T, Bron D
Year : 2021
Journal : J Geriatr Oncol

Immuno-comparative screening of adult-derived human liver stem/progenitor cells for immune-inflammatory-associated molecules.

Authors : Merimi M, Lagneaux L, Lombard CA, Agha DM, Bron D, Lewalle P, Meuleman N, Najimi M, Sokal EM, Najar M
Year : 2021
Journal : Inflamm Res

Biomarkers for Early Diagnosis of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients.

Authors : Debaugnies F, Mahadeb B, Nagant C, Meuleman N, De Bels D, Wolff F, Gottignies P, Salaroli A, Borde P, Voué M, Corazza F
Year : 2021
Journal : J Clin Immunol

New Anti-Leukemic Effect of Carvacrol and Thymol Combination through Synergistic Induction of Different Cell Death Pathways.

Authors : Bouhtit F, Najar M, Moussa Agha D, Melki R, Najimi M, Sadki K, Boukhatem N, Bron D, Meuleman N, Hamal A, Lagneaux L, Lewalle P, Merimi M
Year : 2021
Journal : Molecules
Volume : 26

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Authors : Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, Casasnovas RO, Maerevoet M, Zijlstra J, Follows G, P Vermaat JS, Kalakonda N, Goy AH, Choquet S, Den Neste EV, Hill BT, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Bouabdallah R, Jäger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vasilakopoulos TP, Samal P, Nagy A, Ku M, Canales Albendea MÁ
Year : 2021
Journal : Future Oncol